#	Pagina
attuale pagina	/open-h2020/projects/197891/index.html

Opendata, web and dolomites

MucoVac

Unravelling the mode of action of mucosal adjuvants

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MucoVac project word cloud

Explore the words cloud of the MucoVac project. It provides you a very rough idea of what is the project "MucoVac" about.

signals catalysing public efficient transactivation pathogens onset cross light receptors mode insights antibodies memory vaccination dendritic cell respiratory despite administration lymphocytes safer worldwide performing epithelial immune mucosal shed flagellin innovative therapies unprecedented secretory infectious adjuvant adjuvants constitute characterizing action generate host magnitude agonist longstanding infections talk neutralization laboratory trigger conventional health stimulated urogenital efficacious nasal gastrointestinal port mucosa whereas immunity mid toll mechanism diseases underlying oral diversity suggested safe receptor aid entry paramount vaccines routes latter cells antimicrobial drives

Project "MucoVac" data sheet

The following table provides information about the project.

Coordinator	UNIVERSITE DE LILLE II - DROIT ET SANTE There are not information about this coordinator. Please contact Fabio for more information, thanks.
Coordinator Country	France [FR]
Total cost	185˙076 €
EC max contribution	185˙076 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2014
Funding Scheme	MSCA-IF-EF-ST
Starting year	2016
Duration (year-month-day)	from 2016-09-01 to 2018-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSITE DE LILLE UNIVERSITE DE LILLE Organization address address: 42 RUE PAUL DUEZ city: LILLE postcode: 59800 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LILLE)	coordinator	185˙076.00
2	UNIVERSITE DE LILLE II - DROIT ET SANTE UNIVERSITE DE LILLE II - DROIT ET SANTE Organization address address: RUE PAUL DUEZ 42 city: Lille postcode: 59800 website: www.univ-lille2.fr contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (Lille)	coordinator	0.00

Map

Project objective

The development of new vaccines against infectious diseases is a major worldwide public health objective. Despite the availability of antimicrobial therapies, vaccines still constitute the most effective means of controlling infections. Adjuvants are crucial for increasing the onset, magnitude, diversity and memory of immune responses to vaccines. Whereas a range of adjuvants is available for conventional vaccination routes, there are currently no mucosal adjuvants for promoting the neutralization of respiratory, gastrointestinal or urogenital infections at the pathogens' port of entry. This proposal will focus on (i) performing innovative research on mucosal adjuvants' mode of action and (ii) catalysing the mid-term development of novel, safe, efficient vaccines for nasal or oral administration. Adjuvants that specifically target Toll-like receptors are efficacious in mucosal vaccination because they trigger mucosal immunity (including secretory antibodies). The host laboratory has a longstanding research programme on the mucosal adjuvant activity of a Toll-like receptor 5 agonist (namely flagellin). Recent results have suggested that cross talk between epithelial cells and mucosal dendritic cells drives flagellin's adjuvant activity. The present project aims at identifying (i) signals from flagellin-stimulated epithelial cells that are of paramount importance in the transactivation of dendritic cells, (ii) dendritic cell factors that condition T and B lymphocytes to produce specific mucosal immune responses, and (iii) unique features of memory responses in the mucosa. This proposal will provide unprecedented opportunities for characterizing mucosal adjuvants. Moreover, better knowledge of the mechanism underlying flagellin's action would not only shed light on the latter's properties but also aid the development of better, safer adjuvants. The overall objective is to generate significant new insights into the field of adjuvants and vaccines.

Publications

List of publications.
year	authors and title	journal	last update
2017	Aneesh Vijayan, Martin Rumbo, Christophe Carnoy, Jean-Claude Sirard Compartmentalized Antimicrobial Defenses in Response to Flagellin published pages: , ISSN: 0966-842X, DOI: 10.1016/j.tim.2017.10.008	Trends in Microbiology	2019-07-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MUCOVAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MUCOVAC" are provided by the European Opendata Portal: CORDIS opendata.